June 7th 2023
Combination therapy with nivolumab and relatlimab produces superior progression-free survival vs nivolumab monotherapy among those with advanced melanoma in the phase 3 RELATIVITY-047 trial.
Medical Crossfire ®: Addressing the Top 10 Clinical Challenges in Melanoma
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Medical Crossfire®: Diagnostic and Clinical Considerations in Cutaneous T-Cell Lymphoma for the Dermatologist and the Collaborative Cancer Team
View More
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
View More
Show Me Your Care Plan™: Nursing Considerations for Applying the Latest Approaches Across Care Settings in Melanoma
View More
Eyes and the Periorbital Area Are Vulnerable to Damage From the Sun, Need Special Protection
June 1st 1995NEW YORK--If the face is the area of the body most vulnerable to sun damage, the eyes are in need of special protection, Rene S. Rodriguez-Sains, MD, said at a media conference sponsored by the Skin Cancer Foundation. Malignancies of the eyes and periocular area are particularly serious because of their proximity to the brain and other vital structures, he said.
Cancer Vaccine Made From Purified Tumor Antigen Enters Phase III Melanoma Trials
May 1st 1995NEW YORK--A mollusk protein turned out to be the best carrier for a cancer vaccine being developed by Philip O. Livingston, MD, at Memorial Sloan-Kettering Cancer Center. This approach to augmenting the immunogenicity of the GM2 ganglioside tumor antigen is about to be tested in phase III randomized trials of melanoma patients who are free of detectable disease after surgery but are at high risk for recurrence.
WHO Melanoma Study: Interferon Boosts Disease-Free Survival
March 1st 1995LISBON, Portugal--Adjuvant immunotherapy with low-dose interferon (IFN)-alfa-2a (Roferon-A) boosts disease-free survival by a significant 40% in melanoma patients with regional lymph node metastasis, according to the findings of the latest multicenter World Health Organization (WHO) Melanoma Programme trial.